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Abstract
Background
Earlier puberty is widely linked with future obesity and cardiometabolic disease. We exam-
ined whether age at puberty onset likely influences adiposity and cardiometabolic traits inde-
pendent of childhood adiposity.
Methods and findings
One-sample Mendelian randomisation (MR) analyses were conducted on up to 3,611 white-
European female and male offspring from the Avon Longitudinal Study of Parents and Chil-
dren (ALSPAC) cohort recruited at birth via mothers between 1 April 1991 and 31 December
1992. Time-sensitive exposures were age at menarche and age at voice breaking. Out-
comes measured at age 18 y were body mass index (BMI), dual-energy X-ray absorptiome-
try–based fat and lean mass indices, blood pressure, and 230 cardiometabolic traits derived
from targeted metabolomics (150 concentrations plus 80 ratios from nuclear magnetic reso-
nance [NMR] spectroscopy covering lipoprotein subclasses of cholesterol and triglycerides,
amino acids, inflammatory glycoproteins, and others). Adjustment was made for pre-puber-
tal BMI measured at age 8 y. For negative control MR analyses, BMI and cardiometabolic
trait measures taken at age 8 y (before puberty, and which therefore cannot be an outcome
of puberty itself) were used. For replication analyses, 2-sample MR was conducted using
summary genome-wide association study data on up to 322,154 adults for post-pubertal
BMI, 24,925 adults for post-pubertal NMR cardiometabolic traits, and 13,848 children for
pre-pubertal obesity (negative control). Like observational estimates, 1-sample MR esti-
mates in ALSPAC using 351 polymorphisms for age at menarche (explaining 10.6% of
variance) among 2,053 females suggested that later age at menarche (per year) was asso-
ciated with −1.38 kg/m2 of BMI at age 18 y (or −0.34 SD units, 95% CI −0.46, −0.23; P =
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9.77 × 10−09). This coefficient attenuated 10-fold upon adjustment for BMI at age 8 y, to
−0.12 kg/m2 (or −0.03 SDs, 95% CI −0.13, 0.07; P = 0.55). Associations with blood pressure
were similar, but associations across other traits were small and inconsistent. In negative
control MR analyses, later age at menarche was associated with −0.77 kg/m2 of pre-pub-
ertal BMI measured at age 8 y (or −0.39 SDs, 95% CI −0.50, −0.29; P = 6.28 × 10−13),
indicating that variants influencing menarche also influence BMI before menarche. Cardio-
metabolic trait associations were weaker and less consistent among males and both sexes
combined. Higher BMI at age 8 y (per 1 kg/m2 using 95 polymorphisms for BMI explaining
3.4% of variance) was associated with earlier menarche among 2,648 females (by −0.26 y,
95% CI −0.37, −0.16; P = 1.16 × 10−06), likewise among males and both sexes combined. In
2-sample MR analyses using 234 polymorphisms and inverse variance weighted (IVW)
regression, each year later age at menarche was associated with −0.81 kg/m2 of adult BMI
(or −0.17 SD units, 95% CI −0.21, −0.12; P = 4.00 × 10−15). Associations were weaker with
cardiometabolic traits. Using 202 polymorphisms, later menarche was associated with lower
odds of childhood obesity (IVW-based odds ratio = 0.52 per year later, 95% CI 0.48, 0.57;
P = 6.64 × 10−15). Study limitations include modest sample sizes for 1-sample MR, lack of
inference to non-white-European populations, potential selection bias through modest com-
pletion rates of puberty questionnaires, and likely disproportionate measurement error of
exposures by sex. The cardiometabolic traits examined were heavily lipid-focused and did
not include hormone-related traits such as insulin and insulin-like growth factors.
Conclusions
Our results suggest that puberty timing has a small influence on adiposity and cardiometa-
bolic traits and that preventive interventions should instead focus on reducing childhood
adiposity.
Author summary
Why was this study done?
• People who enter puberty at younger ages are more likely to develop obesity and cardio-
metabolic diseases in adulthood, but whether this is because of puberty timing itself is
unknown.
• Childhood adiposity (fatness) may induce earlier puberty and may also track forward
into adulthood, making childhood adiposity an important potential confounder. Most
prior studies of puberty timing as a risk factor for adult obesity and cardiometabolic
dysfunction did not consider childhood adiposity and used crude measures of cardio-
metabolic traits. They also relied upon observational methods, which are prone to wider
confounding.
Puberty timing, adiposity, and cardiometabolic traits
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002641 August 28, 2018 2 / 25
Funding: JAB and RCR are supported by a Cancer
Research UK programme grant (C18281/A19169);
KHW and NJT by a Wellcome Trust Investigator
grant (202802/Z/16/Z); EEV by a Diabetes UK RD
Lawrence Fellowship (17/0005587); and MVH by a
British Heart Foundation Intermediate Clinical
Research Fellowship (FS/18/23/33512). DC, KHW,
RCR, NJT, and GDS work in/have worked in the
Medical Research Council (MRC) Integrative
Epidemiology Unit at the University of Bristol which
is supported by the MRC (MC_UU_12013/1,3,4,9
(2013–2018); MC_UU_00011/1,5 (2018–2023))
and the University of Bristol. MVH works in a unit
that receives funding from the MRC and the
National Institute for Health Research Oxford
Biomedical Research Centre. The MRC, Wellcome
Trust (102215/2/13/2), and the University of Bristol
provide core support for ALSPAC. GWAS data was
generated by Sample Logistics and Genotyping
Facilities at Wellcome Sanger Institute and LabCorp
(Laboratory Corporation of America) using support
from 23andMe. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: GDS is a member of
the Editorial Board of PLOS Medicine. MVH has
collaborated with Boehringer Ingelheim in
research, and in accordance with the policy of The
Clinical Trial Service Unit and Epidemiological
Studies Unit (University of Oxford), did not accept
any personal payment. There are no further
interests to declare.
Abbreviations: 2SLS, 2-stage least squares;
ALSPAC, Avon Longitudinal Study of Parents and
Children; BMI, body mass index; DBP, diastolic
blood pressure; EGG, Early Growth Genetics;
GIANT, Genetic Investigation of Anthropometric
Traits; GRS, genetic risk score; GWAS, genome-
wide association study; HDL, high-density
lipoprotein; IDL, intermediate-density lipoprotein;
IVW, inverse variance weighted; LDL, low-density
lipoprotein; MR, Mendelian randomisation; NMR,
nuclear magnetic resonance; SBP, systolic blood
pressure; SNP, single nucleotide polymorphism;
VLDL, very low-density lipoprotein; WM, weighted
median.
What did the researchers do and find?
• We used naturally occurring genetic variation in age at menarche to examine whether
puberty timing itself is likely to influence adiposity and cardiometabolic traits.
• Using data from >3,600 offspring from a multigenerational British birth cohort study,
we examined genetically proxied age at menarche/voice breaking in relation to body
mass index, objective fat and lean mass indices, blood pressure, and over 200 detailed
traits from targeted metabolomics. These outcome traits were all measured at age 18 y
(after puberty onset) and at age 8 y (before puberty onset), which allowed us to examine
the effects of puberty timing while accounting for outcome trait levels in childhood.
• We found that apparent effects of later puberty onset on lower adiposity and blood pres-
sure at age 18 y were largely attenuated when accounting for adiposity at age 8 y. Effects
on other cardiometabolic traits were small and inconsistent. We also found a strong
effect of higher adiposity at age 8 y on earlier puberty onset.
What do these findings mean?
• Our findings support puberty timing as a marker, not a driver, of adiposity and cardio-
metabolic trait levels.
• These findings suggest that interventions to prevent adult obesity and cardiometabolic
disease should focus on childhood adiposity, not puberty timing.
Introduction
The onset of puberty is pivotal for human growth and development [1–3]. Beyond immediate
effects on physical and sexual maturity, however, earlier onset of puberty is widely linked with
adverse health outcomes in adulthood. These include greater risk of obesity, hyperinsulinemia,
hyperlipidaemia [4], type 2 diabetes [5], hypertension [4], coronary heart disease [6], and early
mortality [7]. Whether puberty timing is a concern for cardiometabolic health in populations,
however, depends on whether it is truly causal. Higher adiposity in childhood may induce an
earlier puberty [8] and track forward into adulthood [9–13], making it an important potential
confounder. Prospective studies of puberty timing in relation to cardiometabolic outcomes
tend not to account for differences in pre-pubertal adiposity [14,15], and the few studies that
do often find substantial attenuation of puberty–outcome associations [4,16,17]. No studies to
our knowledge have yet examined puberty timing in relation to detailed traits from targeted
metabolomics in adulthood, and, importantly, evidence has so far been observational, with
inherent susceptibilities to residual confounding.
Direct manipulation of puberty timing to examine its cardiometabolic effects within a ran-
domised controlled trial setting would be costly, time intensive, and potentially unethical, and
such interventions have not been performed on non-human mammals. Advances in human
population genetics do, however, allow us to employ Mendelian randomisation (MR)—an
instrumental variable method that exploits the random assignment of exposure-associated risk
alleles. This method is by nature less prone to confounding and reverse causation bias, which
Puberty timing, adiposity, and cardiometabolic traits
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limit causal inference from observational data [18–20]. Nearly 400 common genetic variants
so far associate strongly and independently with age at menarche among females [21]. Nearly
half of these variants also associate with age at voice breaking among males, corroborating
functional work that indicates a heavily overlapping genetic and molecular architecture of
puberty timing between sexes [1,21,22]. Of concern, however, is the high degree of genetic
overlap between puberty timing and adiposity [21], which challenges our ability to examine
effects of puberty timing variants that operate exclusively through puberty timing—a core
assumption of MR. Multivariate MR methods exist [23] but carry risk of inducing serious bias
in this instance through stratification on a potential mediator (post-pubertal adiposity) [24].
Given the time-sensitive nature of pubertal age, it would be advantageous to account for a pre-
pubertal measure of adiposity within an MR setting as this may help to further address
confounding.
This study aimed to determine whether puberty timing is likely to have a distinct influence
on adiposity and cardiometabolic traits in adulthood. First, we used data from a British birth
cohort study (the Avon Longitudinal Study of Parents and Children [ALSPAC]) to examine
observational estimates of age at menarche among females in relation to adiposity and a large
set of cardiometabolic traits measured at age 18 y, accounting for pre-pubertal body mass
index (BMI) measured at age 8 y. We then examined 1-sample MR estimates of age at menar-
che in relation to adiposity and cardiometabolic traits, also accounting for pre-pubertal BMI.
Data from international genome-wide association study (GWAS) consortia were used for rep-
lication of MR estimates.
Methods
Study population
Data on offspring from ALSPAC were used for the main analyses. ALSPAC is a population-
based birth cohort study in which 14,541 pregnant women with an expected delivery date
between 1 April 1991 and 31 December 1992 were recruited from the former Avon county of
southwest England. Since then, the mothers and their offspring (N = 13,988 who were alive at
1 y) have been followed repeatedly with questionnaire- and clinic-based assessments [25], with
an additional 713 children enrolled over the course of the study. Non-sibling participants were
considered for the present analyses (excluding 202 non-first-borns). A further 604 participants
of a non-white ethnicity were excluded to minimise the confounding of associations by ances-
tral population structure. Participants provided written informed consent, and ethical
approval was obtained from the ALSPAC Law and Ethics Committee and the local research
ethics committee. Cohort details and data descriptions are publicly available (http://www.
bristol.ac.uk/alspac/researchers/access).
Prespecified study protocol
A study protocol was written in December 2016 for an ALSPAC data proposal prior to analy-
ses (S1 Protocol) as part of wider investigations into puberty timing and cancer. Analyses that
were not prespecified but added following peer review included 1-sample MR analyses of BMI
with summary cardiometabolic trait outcomes for sample power comparisons, funnel plots of
polymorphisms for age at menarche in relation to adult adiposity and blood pressure to assess
heterogeneity, multivariate MR of age at menarche and childhood BMI in relation to adult adi-
posity and blood pressure to compare estimates with main results, and 2-sample MR of the
effect of age at menarche on childhood obesity.
Puberty timing, adiposity, and cardiometabolic traits
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Assessment of puberty timing
Among females, puberty timing was indicated by the age (in years) at which menarche
occurred. Data were reported by females through questionnaires distributed annually from the
ages of 8 y to 17 y, covering the expected duration of puberty. The earliest report of age at men-
arche was used for analyses when several were available, assuming this to be closer to the event
and thus most accurate. Among males, puberty timing was indicated by the age (in years) at
which voice breaking occurred. Items from annual questionnaires asked whether voice
changes had partially or totally occurred by the time of assessment but not the specific age of
occurrence; we therefore estimated age at voice breaking by taking the age at which any stage
of voice breaking (partial or total) was first reported and subtracting 6 months from this age to
represent the midpoint between this occasion of first report and the occasion immediately
prior. In cases where data on this most recent prior occasion were missing yet data on an older
occasion were not, this subtraction was increased to 12 months, 24 months, etc., to reflect the
midpoint between the occasion of first report and the most recent prior occasion known.
Assessment of genotype and genetic instruments
Genotype was assessed using the Illumina HumanHap550 quad chip platform. After quality
control through exclusion of participants with sex mismatch, minimal or excessive heterozy-
gosity, disproportionately missing data, insufficient sample replication, cryptic relatedness,
and non-European ancestry, 500,527 single nucleotide polymorphisms (SNPs) were measured
directly. Imputation using the 1000 Genomes reference panel from the Impute2 repository
resulted in coverage of 8,099,747 SNPs after further quality control.
An instrument for puberty timing was constructed within a 1-sample MR framework
[18,26,27] using genetic variants robustly and independently associated with age at menarche
in the largest GWAS to date, which meta-analysed imputed genomic scans of self-reported age
at menarche (in years, unadjusted for BMI) from 329,345 post-pubertal women from 42 cohort
studies [21]. A total of 389 independent variants reached a P-value threshold for genome-wide
significance (P< 5 × 10−8) in a discovery sample; these were largely replicated in a separate
sample of 39,543 post-pubertal women from the Icelandic deCODE study, explaining 7.4% of
the variance in age at menarche in the replication sample. Of these 389 variants, 363 were
SNPs (not deletion/insertion polymorphisms). Twelve of these SNPs were not available in
ALSPAC imputed genotype files, leaving 351 SNPs for instrumentation. A genetic risk score
(GRS) was constructed using PLINK 1.9 software, specifying the effect (age at menarche–rais-
ing) allele and beta coefficients from the source GWAS as external weightings. Scoring was
done by multiplying the number of effect alleles (or probabilities of effect alleles if imputed) at
each SNP (0, 1, or 2) by its weighting, summing these, and dividing by the total number of
SNPs used. The score therefore reflects the average per-SNP effect on age at menarche. Among
1,831 females eligible for analyses in ALSPAC, this score was associated with measured age at
menarche (P = 1.87 × 10−46), explaining 10.6% of the variance (F = 216.8). It was less strongly
associated with age at voice breaking among 1,312 males (P = 0.01), explaining 0.50% of the
variance (F = 6.5). Among 3,143 females and males combined, this score was associated with
age at puberty onset (P = 2.18 × 10−18), explaining 2.4% of the variance (F = 77.5). This GRS
was also directly associated with BMI at age 18 y among females (P = 3.44 × 10−06), among
males (P = 0.002), and among both sexes combined (P = 1.37 × 10−07).
A refined GRS for puberty timing was also considered based on SNPs associated genome-
wide with age at menarche that were also associated (at P< 0.05) with age at voice breaking
(measured in years) in a separate sample of 55,871 males in the 23andMe study [21], to better
represent exposure among males. Of 119 SNPs, 115 were available in ALSPAC imputed
Puberty timing, adiposity, and cardiometabolic traits
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genotype files for instrumentation. This refined GRS was similarly associated with age at voice
breaking among males as the full GRS (P = 0.01) and explained a similarly low amount of vari-
ance (0.58%, F = 7.7). Its P-value for direct association with BMI at age 18 y was 0.11.
A GRS for BMI was also constructed using SNPs associated genome-wide with adult BMI
from the most recent meta-analysis of the Genetic Investigation of Anthropometric Traits
(GIANT) consortium, which comprises 322,154 men and women from 114 cohort studies
[28], using the same methods described above. Of 97 SNPs, 95 were available in ALSPAC
imputed genotype files for instrumentation. Among 3,171 females and males in ALSPAC, this
score was associated with BMI measured at age 8 y (P = 6.62 × 10−26), explaining 3.44% of the
variance (F = 112.8).
Assessment of adiposity and cardiometabolic traits
Height and weight were measured while in light clothing and without shoes during each
clinic visit from age 3 y onwards; data from approximate ages of 8 y and 18 y were used in the
present analyses. Weight was recorded to the nearest 0.1 kg using a Tanita scale, and height to
the nearest 0.1 cm using a Harpenden stadiometer. BMI was calculated based on weight (in
kilograms) divided by the square of height (in meters). Participants also underwent body
composition scanning with dual-energy X-ray absorptiometry using a Lunar Prodigy narrow
fan beam densitometer, from which estimates of total body fat and lean mass (in kilograms)
were obtained. Fat mass index and lean mass index were derived in the same way as for BMI
(in kg/m2).
Systolic and diastolic blood pressure (SBP and DBP, respectively) were additionally exam-
ined twice in succession while seated and at rest, with the arm supported, using a cuff and
DINAMAP 9301 device; the mean of these 2 measures represented resting blood pressure.
Blood samples were drawn during these same 2 clinic visits, the age 8 y sample while not
fasting and the age 18 y sample while fasting (the metabolic trait concentrations included
in the study have shown stability over different durations of fasting time [29]). Proton
nuclear magnetic resonance (NMR) spectroscopy as part of a targeted high-throughput
metabolomics platform [30] was performed on both blood samples to quantify 230 cardiome-
tabolic traits (150 concentrations plus 80 ratios) comprising lipoprotein cholesterol subclass
particle concentrations and sizes, glycerides and phospholipids, apolipoproteins, fatty acids,
glycolysis-related factors, amino acids, ketone bodies, and factors related to fluid balance and
inflammation.
Assessment of covariates
Covariates considered were basic demographic variables of participant age (in months) at the
time of each outcome trait assessment and the highest level of education attained by their
mother as answered by her through questionnaire after birth (grouped based on English stan-
dards as Certificate of Secondary Education, vocational, O level, A level, or degree) as an indi-
cator of childhood socioeconomic position. Health behaviour covariates were not considered
due to individual differences in exposure timing.
Statistical analyses
The conceptual framework of this study is outlined in Fig 1.
In observational analyses, linear regression models were used to examine age at menarche/
voice breaking (in years) separately among females and males in relation to the dependent var-
iables BMI, fat mass index, lean mass index, SBP, DBP, and other cardiometabolic traits, mea-
sured at approximately age 18 y. Outcomes were standardised (mean = 0, SD = 1) to allow
Puberty timing, adiposity, and cardiometabolic traits
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comparability of effect sizes, and robust standard errors were used to accommodate skewed
outcome distributions [31]. The following models were constructed: (i) adjusted for age (in
months) at outcome assessment and maternal education; (ii) adjusted for age, maternal educa-
tion, and BMI measured at age 8 y, to examine whether puberty timing is associated with out-
comes at age 18 y independent of pre-pubertal BMI; and (iii) adjusted for age, maternal
education, and the age 8 y value of the specific outcome trait being examined at age 18 y, to
examine whether puberty timing is associated with post-pubertal outcomes independent of
pre-pubertal values of those same traits. Observational analyses were repeated among females
and males combined.
One-sample MR analyses were first conducted among females only, given the greater
strength of age at menarche instruments. Two-stage least squares (2SLS) regression models
with robust standard errors were used to examine the full GRS for age at menarche (351 SNPs
with external weightings) as an instrument for age at menarche in relation to the outcomes of
BMI, fat mass index, lean mass index, SBP, DBP, and other cardiometabolic traits at age 18 y.
The following models were constructed: (i) unadjusted; (ii) adjusted for measured BMI at age
8 y (in both first- and second-stage models), to examine whether instrumented age at menar-
che is associated with outcomes at age 18 y independent of pre-menarche BMI; and (iii)
adjusted for the age 8 y value of the specific outcome trait being examined at age 18 y, to exam-
ine whether instrumented age at menarche is associated with post-menarche outcomes inde-
pendent of pre-menarche values of those specific traits. These models were repeated among
females and males combined (based on age at menarche/voice breaking, respectively) to exam-
ine whether greater sample size improves the precision of results despite reduced instrument
strength. Models were also repeated using the refined GRS for age at menarche (115 SNPs also
associated with age at voice breaking among males) among males only.
In the second set of 1-sample MR analyses, 2SLS models with robust standard errors were
used to examine the full GRS for age at menarche as an instrument for age at menarche among
females in relation to BMI, fat mass index, lean mass index, SBP, DBP, and other cardiometa-
bolic traits measured at age 8 y (before menarche). This analysis served as a negative control
analysis intended to illustrate the extent of pleiotropy within the genetic instrument, given that
any associations of instrumented age at menarche with traits measured before menarche can-
not be generated by age at menarche itself (because this is temporally implausible). These mod-
els were repeated on females and males combined.
In the third set of 1-sample MR analyses, 2SLS models with robust standard errors were
used to examine the GRS of 95 SNPs for BMI as an instrument for BMI at age 8 y in relation to
age at puberty onset among females, among males, and among both sexes combined.
Fig 1. Conceptual framework of this study.
https://doi.org/10.1371/journal.pmed.1002641.g001
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All analyses described above were performed on unrestricted samples of participants (sam-
ple sizes varying across models). To examine the extent to which potentially non-randomly
missing data biased results, all models were repeated on complete case samples of participants
with all relevant data.
To gauge the adequacy of ALSPAC sample power to generate reliable 1-sample MR esti-
mates, we examined estimates for BMI at age 8 y and 18 y (each standardised, given dissimilar
variance over time) in relation to standardised summary cardiometabolic traits at age 8 y and
18 y. Strong evidence of association is expected for BMI at least in relation to SBP, DBP, and
triglycerides, based on known effects among young adults [12], if the sample is adequately
powered.
For comparison with 1-sample MR estimates based on measured pre-pubertal BMI adjust-
ments, we performed multivariate MR analyses of age at menarche in relation to adiposity and
blood pressure at age 18 y using genetically predicted trait adjustments in ALSPAC. For unad-
justed models, genetically predicted age at menarche and childhood BMI were first derived by
regressing each exposure trait with its externally weighted GRS as an independent variable
(using the same SNP inclusion criteria as prior). Predicted values from first-stage regressions
were then used as independent variables in relation to outcome traits in second-stage models.
For multivariate adjusted models, genetically predicted age at menarche and childhood BMI
were first derived by regressing each exposure trait with both externally weighted GRSs as 2
independent variables. Predicted values from first-stage regressions were then used as inde-
pendent variables in relation to outcome traits in second-stage models [32].
Given the large number of statistical tests performed and the correlated nature of outcome
traits, the P-value threshold of 0.05 commonly used for guiding nominal statistical significance
can be corrected for multiple testing using the Bonferroni method assuming 33 independent
tests (the number of principle components explaining 95% of the variance in the cardiometa-
bolic outcomes studied here in previous multi-cohort analyses [12]); the P-value threshold for
statistical significance becomes P< 0.002. Here, P-values were interpreted as continuous indi-
cators of the strength of evidence against the null hypothesis [33], with effect size and precision
considered most informative. Analyses were conducted using Stata 14 (StataCorp).
Replication analyses
As a replication analysis for 1-sample MR, 2-sample MR was additionally carried out using
summary-level GWAS data available through the MR-Base platform (http://www.mrbase.org)
[34]. Data for BMI were from the GIANT consortium [28], described above, representing
322,154 post-pubertal females and males. Data for cardiometabolic traits were from Kettunen
et al. [35], based on trait concentrations derived from an NMR-based metabolomics platform
(the same used for the above ALSPAC analyses) on 13,171 to 24,925 post-pubertal females and
males from 14 cohort studies. Following additional SNP pruning for high linkage disequilib-
rium (LD) using R2 < 0.01 within a 10,000-kb distance to satisfy modelling criteria, inverse
variance weighted (IVW) regression models were used to produce estimates of linear associa-
tion (assuming no sample overlap and the same underlying population [20]). Coefficients
were interpreted as standardised mean differences in outcome per year later age at menarche
[21]. When an exposure-associated SNP was absent in the outcome GWAS, a proxy SNP in
high LD (R2 0.80) was used with the same criteria as above [34]. If no proxy SNP was avail-
able, then that SNP was excluded. Because of this and possible allele harmonisation issues, the
number of instruments used for estimates varies and is reported. Where IVW coefficients
showed strong evidence of effect, results from 2 sensitivity models were examined to account
for directional pleiotropy. The first was MR-Egger regression [36], which tests for differences
Puberty timing, adiposity, and cardiometabolic traits
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from a 0 intercept representing the average pleiotropic effect across all variants assuming that
pleiotropic effects on the outcome are independent of their effects on the exposure; the slope
provides an estimate of association magnitude allowing all such variants to be pleiotropic. The
second sensitivity method was weighted median (WM) regression [37], which is interpreted
similarly to IVW models but allows the weight of up to half of the contributing variants to be
pleiotropic and is less influenced by outliers. To complement negative control 1-sample MR
analyses for adiposity, we also examined the effect of later menarche on childhood obesity,
defined as a95th percentile BMI value (versus <50th percentile BMI value) using outcome
data on 13,848 children (mean age across 14 cohorts = 2–10 y) from the Early Growth Genetics
(EGG) consortium [38]. Analyses were performed using R-Studio 1.0.44 (R version 3.3.2) and
publicly available code (TwoSampleMR; https://mrcieu.github.io/TwoSampleMR).
Results
Sample characteristics
Characteristics of ALSPAC females who were eligible for any analysis (i.e., who had data on
age at menarche, covariates, at least 1 adiposity indicator, and at least 1 cardiometabolic trait)
are shown in Table 1. Among 2,112 females, age at menarche ranged from 8 y to 16 y (mean =
12.37 y). Among 1,499 males, age at voice breaking ranged from 9.08 y to 16.67 y (mean =
13.21 y) (S1 Table). Females and males who had missing data on age at menarche/voice break-
ing but were otherwise eligible for inclusion in analyses had lower maternal education but
showed no clear difference in adiposity and cardiometabolic traits (S2 Table).
Observational associations of age at menarche with adiposity and
cardiometabolic traits at age 18 y
Females in the latest versus earliest group of age at menarche had a lower BMI at 18 y (22.04
versus 24.39 kg/m2, P = 4.53 × 10−20), a difference already apparent at age 8 y (15.71 versus
17.21 kg/m2, P = 4.41 × 10−29; Table 1). In models adjusting for age and maternal education
among 2,230 females (S3 Table; Fig 2), each year later age at menarche was associated with
−0.81 kg/m2 of BMI at age 18 y (or −0.20 SD-units, 95% CI −0.24, −0.17; P = 5.91 × 10−29).
Upon additional adjustment for BMI at age 8 y to account for differences in pre-pubertal BMI,
this coefficient attenuated 4-fold from −0.81 kg/m2 to −0.20 kg/m2 (or −0.05 SDs, 95% CI
−0.07, −0.02; P = 0.002). Patterns were similar for fat mass index but less apparent for lean
mass index. Similar results were seen among males based on age at voice breaking: lower BMI
was already observed at age 8 y with later voice breaking (S1 Table), and associations of later
voice breaking with lower BMI at age 18 y attenuated upon adjustment for BMI at age 8 y (S4
Table). These associations were weaker among females and males combined than among the
sexes separately (S5 Table).
Differences in summary cardiometabolic traits at age 18 y and at age 8 y among females in
the latest versus earliest group of age at menarche were small, being largest for SBP and DBP
(Table 1). In models adjusting for age and maternal education on up to 2,087 females (S3
Table; Figs 2–4), associations of later age at menarche with other cardiometabolic traits at age
18 y were generally small in magnitude, with moderate-to-high P-values. The direction of the
effect with later age at menarche was inconsistent across very low-density lipoprotein (VLDL)
traits, but was generally positive across intermediate-density lipoprotein (IDL), low-density
lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, and fatty acid traits, and neg-
ative across SBP, DBP, and amino acid traits. The largest effect size was observed with DBP, at
−0.63 mm Hg (or −0.10 SD-units, 95% CI −0.13, −0.06; P = 1.00 × 10−07). Attenuation was
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slight when adjusting for BMI at age 8 y, and when adjusting for specific outcome trait values
at age 8 y (S1–S3 Figs) (e.g., the coefficient for DBP at age 18 y reduced from −0.63 mm Hg to
−0.38 mm Hg when adjusting for BMI at age 8 y, and from −0.63 mm Hg to −0.50 mm Hg
when adjusting for DBP at age 8 y). Among males, associations of age at voice breaking with
cardiometabolic traits were generally smaller in magnitude; attenuations were slight upon
adjustment for BMI at age 8 y and for specific outcome traits at age 8 y (S4 Table), likewise
among females and males combined (S5 Table; S4–S9 Figs).
One-sample MR of age at menarche for adiposity and cardiometabolic
traits at age 18 y
Using the full GRS as an instrument among 2,053 females (S6 Table; Fig 2), each year later age
at menarche was associated with −1.38 kg/m2 of BMI at age 18 y (or −0.34 SD-units, 95% CI
−0.46, −0.23; P = 9.77 × 10−09). Effect size was larger for fat mass index (at −1.11 kg/m2) than
for lean mass index (at −0.28 kg/m2). Upon adjustment for measured BMI at age 8 y, the
Table 1. Characteristics of females by age at menarche group in ALSPAC at age 8 y and 18 y.
Characteristic Age at menarche among females
Sample mean (SD) = 12.37 y (1.12 y)
P-value
Earliest
(8–11 y)
N = 447
Intermediate
(12 y)
N = 722
Latest
(13–16 y)
N = 943
Intermediate versus earliest Latest versus earliest
Mother has no further academic education—N (%) 249 (55.70) 384 (53.19) 493 (52.28) 0.40 0.23
After puberty onset (age 18 y assessment)
Body mass index (kg/m2)—mean (SD) 24.39 (4.73) 23.15 (4.30) 22.04 (3.67) 6.76 × 10−06 4.53 × 10−20
Fat mass index (kg/m2)—mean (SD) 9.06 (3.76) 8.08 (3.32) 7.21 (3.04) 7.85 × 10−06 4.70 × 10−19
Systolic blood pressure (mm Hg)—mean (SD) 111.07 (8.19) 110.23 (7.84) 109.23 (7.58) 0.09 7.70 × 10−05
Diastolic blood pressure (mm Hg)—mean (SD) 66.30 (6.22) 64.97 (6.20) 64.34 (5.76) 4.42 × 10−04 3.19 × 10−08
Triglycerides (mmol/l)—mean (SD) 0.93 (0.32) 0.92 (0.31) 0.92 (0.31) 0.54 0.60
HDL cholesterol (mmol/l)—mean (SD) 1.47 (0.23) 1.49 (0.23) 1.50 (0.23) 0.22 0.05
LDL cholesterol (mmol/l)—mean (SD) 1.12 (0.35) 1.14 (0.35) 1.16 (0.36) 0.39 0.15
Total cholesterol (mmol/l)—mean (SD) 3.71 (0.65) 3.76 (0.65) 3.80 (0.68) 0.30 0.08
Glucose (mmol/l)—mean (SD) 4.06 (0.36) 4.04 (0.31) 4.05 (0.41) 0.42 0.68
Glycoprotein acetyls (mmol/l)—mean (SD) 1.26 (0.15) 1.24 (0.13) 1.24 (0.13) 0.11 0.06
Before puberty onset (age 8 y assessment)
Body mass index (kg/m2)—mean (SD) 17.21 (2.32) 16.42 (2.13) 15.71 (1.72) 6.03 × 10−08 4.41 × 10−29
Fat mass index (kg/m2)—mean (SD) 5.91 (2.32) 5.01 (2.26) 4.26 (2.02) 2.68 × 10−09 1.47 × 10−31
Systolic blood pressure (mm Hg)—mean (SD) 100.88 (9.93) 99.02 (9.18) 97.73 (8.72) 0.003 1.25 × 10−07
Diastolic blood pressure (mm Hg)—mean (SD) 57.79 (6.67) 57.07 (6.56) 56.29 (6.34) 0.09 2.21 × 10−04
Triglycerides (mmol/l)—mean (SD) 1.09 (0.42) 1.09 (0.36) 1.06 (0.36) 0.98 0.27
HDL cholesterol (mmol/l)—mean (SD) 1.45 (0.21) 1.48 (0.19) 1.50 (0.20) 0.02 0.001
LDL cholesterol (mmol/l)—mean (SD) 1.23 (0.31) 1.29 (0.36) 1.27 (0.32) 0.03 0.09
Total cholesterol (mmol/l)—mean (SD) 3.94 (0.58) 4.04 (0.62) 4.02 (0.59) 0.04 0.06
Glucose (mmol/l)—mean (SD) 4.17 (0.51) 4.14 (0.47) 4.11 (0.51) 0.40 0.14
Glycoprotein acetyls (mmol/l)—mean (SD) 1.27 (0.14) 1.25 (0.13) 1.23 (0.14) 0.06 0.001
Sample sizes vary as participants described are those with data on age at menarche, covariates, at least 1 adiposity trait, and at least 1 cardiometabolic trait. Age at
menarche was self-reported rounded down to the nearest whole year; the mean value was calculated from these values. ‘No further academic education’ defined as
highest level of education attained being Certificate of Secondary Education, vocational, or O level (not A level or degree).
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1002641.t001
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coefficient for BMI at 18 y attenuated over 10-fold from −1.38 kg/m2 to −0.12 kg/m2 (or −0.03
SDs, 95% CI −0.13, 0.07; P = 0.55), with similar attenuations for fat and lean mass indices and
upon adjustment for specific outcome trait values at age 8 y (S1–S3 Figs). Among females and
males combined, attenuation of the coefficient for BMI was also evident, but with a greater effect
on lean mass index than on fat mass index (S7 Table; S7 Fig). Similar results were seen when
using the refined GRS among males (S8 Table). Results of a multivariate MR model using full
GRSs among females (S9 Table) showed a similar unadjusted effect of later genetically predicted
age at menarche on BMI at age 18 y (−0.28 SD-units, 95% CI −0.36, −0.19; P = 2.92 × 10−10) and a
similar near-complete attenuation of this effect upon adjustment for genetically predicted BMI at
age 8 y (to −0.001 SD-units, 95% CI −0.10, 0.10; P = 0.99). In this multivariate model, higher
genetically predicted BMI at 8 y showed an expectedly greater effect on BMI at 18 y; this effect
was minimally attenuated upon adjustment for genetically predicted age at menarche.
Using the full GRS among females, effect sizes for later age at menarche for cardiometabolic
traits were close to 0, with the direction of coefficients being inconsistent across VLDL traits;
Fig 2. Associations of age at menarche with adiposity and blood pressure at age 18 y among females in ALSPAC.
https://doi.org/10.1371/journal.pmed.1002641.g002
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positive across IDL, LDL, HDL, triglyceride, and fatty acid traits; and negative across SBP, DBP,
and amino acid traits (S6 Table; Figs 5 and 6). Substantial attenuation of coefficients for SBP
and DBP was seen with adjustment for BMI at age 8 y; this attenuation was less pronounced
when adjusting for genetically predicted BMI at age 8 y in a multivariate MR model (S9 Table).
Attenuations showed no clear pattern across other cardiometabolic traits. Attenuations were
similarly unclear with adjustment for specific outcome trait values at age 8 y (S1–S3 Figs).
Among females and males combined (S7 Table; S4–S9 Figs), associations with cardiometabolic
traits were more pronounced, with effect size being largest for SBP, at −3.88 mm Hg (or −0.40
SD-units, 95% CI −0.59, −0.22; P = 2.00 × 10−05), and for citrate, at 0.40 SD-units (95% CI 0.19,
0.61; P = 1.55 × 10−40). Attenuations, if any, were modest with adjustment for BMI at age 8 y
but were more substantial with adjustment for specific outcome trait values at age 8 y. Using the
refined GRS of 115 SNPs as an instrument among males (S8 Table), associations were generally
weaker with adiposity and cardiometabolic traits, with greater inconsistency and imprecision
than when using the full GRS among females and among both sexes combined, both before and
after adjustment for BMI at age 8 y and for specific outcome trait values at age 8 y.
Negative control 1-sample MR of age at menarche for adiposity and
cardiometabolic traits at age 8 y
Using the full GRS among females (Fig 7; S10 Table), each year later age at menarche was asso-
ciated with −0.77 kg/m2 of BMI (or −0.39 SDs, 95% CI −0.50, −0.29; P = 6.28 × 10−13) mea-
sured at age 8 y. Effect sizes were similar for fat and lean mass indices, and were relatively high
Fig 3. Observational associations of age at menarche with lipid cardiometabolic traits at age 18 y among females in ALSPAC. HDL, high-density lipoprotein; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; XL VLDL, chylomicrons and extremely large very low-density
lipoprotein.
https://doi.org/10.1371/journal.pmed.1002641.g003
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for SBP, at −1.73 mm Hg (or −0.19 SD-units, 95% CI −0.30, −0.08; P = 4.94 × 10−04), and DBP,
at −1.13 mm Hg (or −0.17 SD-units, 95% CI −0.27, −0.07; P = 1.25 × 10−03), measured at age 8
y. Associations with other cardiometabolic traits at age 8 y were of a similar or higher magni-
tude to those seen at age 18 y (S10 Fig). Associations using the full GRS were of a larger magni-
tude among females and males combined than among females only (S11 Table; S11 and S12
Figs), likewise when using the refined GRS as an instrument among males (S12 Table).
One-sample MR of pre-pubertal adiposity for age at puberty onset
Using the GRS of 95 SNPs for BMI as an instrument, higher BMI (per 1 kg/m2) at age 8 y was
associated with an earlier age at menarche among 2,648 females, at −0.26 y (95% CI −0.37,
−0.16; P = 1.16 × 10−06); an earlier age at voice breaking among 2,150 males, at −0.33 y (95%
CI −0.57, −0.09; P = 0.01); and an earlier age at puberty onset among females and males com-
bined, at −0.27 y (95% CI −0.39, −0.16; P = 3.43 × 10−06).
Additional analyses
Results of complete case analyses for all above analyses are presented in S3–S12 Tables. Obser-
vational associations among a consistent sample of 664 females and 605 males were similar as
among unrestricted samples; the largest effect sizes for later age at menarche were for BMI, fat
mass index, lean mass index, SBP, and DBP at age 18 y, with similar attenuation patterns seen
with adjustment for BMI and specific outcome trait values at age 8 y. Estimates from 1-sample
MR models among a consistent sample of 629 females were similar as among unrestricted
samples, as were those among a consistent sample of 1,193 females and males.
In additional analyses for power comparisons (S13 Table), higher BMI at age 8 y (per SD-
unit higher) among males and females combined was expectedly associated with higher SBP
Fig 4. Observational associations of age at menarche with non-lipid cardiometabolic traits at age 18 y among females in ALSPAC.
https://doi.org/10.1371/journal.pmed.1002641.g004
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(at 0.47 SD-units, 95% CI 0.33, 0.61; P = 3.75 × 10−11) and higher DBP (at 0.35 SD-units, 95%
CI 0.20, 0.50; P = 5.93 × 10−06) at age 8 y. These associations were weaker but directionally con-
cordant at age 18 y. Associations were also relatively strong with glycoprotein acetyls, HDL-
cholesterol, triglycerides, and glucose. These associations were most consistent by sex for BMI
with SBP, DBP, and glycoprotein acetyls.
Funnel plots of individual SNP-based effects of later age at menarche on adiposity and
blood pressure at age 18 y (those outcomes with the strongest evidence of association in prior
analyses) are shown in S13–S17 Figs. Effects were generally symmetrical around 0 for each out-
come, with attenuations upon adjustment for measured BMI at age 8 y appearing general
rather than SNP-specific. Some extreme outliers existed but carried the lowest 1/SE values,
indicating the lowest precision.
Replication analyses
Of 363 instrumentable SNPs for age at menarche identified in the source GWAS, up to 303
were available in summary-level outcome data after pruning. Based on IVW models using 234
SNPs and summary-level data for adult BMI, each year later age at menarche was associated
with −0.81 kg/m2 of adult BMI (or −0.17 SD units, 95% CI −0.21, −0.12; P = 4.00 × 10−15; S14
Table). The Cochran Q-statistic for heterogeneity in this overall IVW estimate was 1,721.5 (P
= 5.33 × 10−225), indicating a high degree of heterogeneity in individual SNP effects. The
MR-Egger intercept did not differ from 0 however (P = 0.83), suggesting that individual SNP
heterogeneity was largely balanced (no directional pleiotropy). Corresponding effect estimates
Fig 5. Mendelian randomisation of age at menarche for lipid cardiometabolic traits at age 18 y among females in ALSPAC. HDL, high-density lipoprotein; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; XL VLDL, chylomicrons and extremely large very low-density
lipoprotein.
https://doi.org/10.1371/journal.pmed.1002641.g005
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Fig 6. Mendelian randomisation of age at menarche for non-lipid cardiometabolic traits at age 18 y among females in ALSPAC.
https://doi.org/10.1371/journal.pmed.1002641.g006
Fig 7. Negative control Mendelian randomisation of age at menarche for adiposity and blood pressure at age 8 y among females in ALSPAC.
https://doi.org/10.1371/journal.pmed.1002641.g007
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from MR-Egger and WM sensitivity models were −0.18 SD units (95% CI −0.30, −0.06; P =
0.003) and −0.04 SD units (95% CI −0.06, −0.02; P = 0.002) of BMI, allowing for directional
pleiotropy in up to 100% and 50% of genetic weights, respectively. Based on 202 SNPs, later
menarche was associated with lower odds of childhood obesity in the EGG consortium data
(IVW-based odds ratio = 0.52 per year later, 95% CI 0.48, 0.57; P = 6.64 × 10−15). Individual
SNP heterogeneity was apparent (IVW Q = 384.7; P = 1.19 × 10−13), with 137 SNPs exerting a
negative effect and 67 exerting a positive effect. This heterogeneity did not appear unbalanced
(MR-Egger intercept P = 0.56).
Effect sizes for associations of age at puberty onset with adult cardiometabolic traits were
generally low in magnitude (absolute values between 0.01 to 0.04 SD units). The direction of
effects related to later age at menarche was generally negative across VLDL, IDL, and LDL
traits, positive across HDL traits, and negative across fatty acids and amino acids. Using 82
SNPs as instruments for both age at menarche and voice breaking (S15 Table) resulted in a
similar magnitude of association of later puberty onset with lower BMI, at −0.16 SD units
(95% CI −0.24, −0.08; P = 4.33 × 10−05). The MR-Egger intercept did not differ from 0 (P =
0.93), and MR-Egger and WM models estimated the association as being −0.17 SD units (95%
CI −0.37, 0.03; P = 0.10) and −0.04 SD units (95% CI −0.08, −0.00; P = 0.06), respectively.
Association magnitudes with cardiometabolic traits were similar but generally more modest
using 104 SNPs for both age at menarche and voice breaking (S15 Table).
Discussion
We sought in this study to determine whether puberty timing is likely to have a distinct influ-
ence on adiposity and cardiometabolic traits in adulthood. To do this, we used both observa-
tional and genetically informed methods, which together allow more reliable inference on
causality than previously possible. Our results suggest that apparent effects of puberty timing
on adiposity and cardiometabolic traits in adulthood are largely confounded by pre-pubertal
adiposity and are not likely driven by puberty timing itself. Strong evidence was also found for
an effect of higher pre-pubertal adiposity on earlier age at puberty onset. These findings
together point to childhood adiposity as a primary intervention target.
Our first set of analyses used observational data on age at menarche among females and age
at voice breaking among males in relation to adiposity measured at age 18 y. Results suggested
that later menarche among females was associated with lower subsequent adiposity (assessed
using both BMI and objective fat mass), but that these associations were largely statistically
accounted for by differences in adiposity at age 8 y, and thereby reflect known tendencies
within individuals for adiposity levels in childhood to track forward to later life stages [9,10].
We also examined over 200 detailed cardiometabolic traits in adulthood using the same
approach, generally finding weaker evidence for associations and some attenuation of already
small effect sizes when accounting for pre-pubertal trait values, again suggesting that metabolic
disturbances likely predate puberty onset. Associations were similar albeit weaker among
males, possibly due to greater measurement error in age at voice breaking.
Our second set of analyses used genetic variants as instruments for puberty timing within a
1-sample MR framework to minimise issues of confounding. However, since genetic variants
for age at menarche are expected to be pleiotropic with BMI [21], these MR estimates were fur-
ther adjusted for BMI at age 8 y, which should help further address residual confounding since
this measure preceded the onset of puberty (a time-sensitive exposure). Unadjusted results
among females suggested a causal effect of later menarche on lower adult adiposity as reported
previously [21,39], but this effect was almost completely attenuated with adjustment for BMI
measured at age 8 y, supporting confounding by pre-pubertal adiposity. The time-sensitive
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nature of puberty timing as an exposure also allowed us to conduct negative control MR analy-
ses, whereby pre-pubertal traits were examined as outcomes to confirm the non-existence of
effects that should not exist if age at puberty onset were a distinct exposure with valid instru-
ments. Any effects of puberty timing on traits measured before puberty onset must be gener-
ated not by puberty timing itself (because it is temporally implausible) but by confounding
factors. Results of these negative control analyses suggested apparent effects of later menarche
on lowering pre-menarche adiposity and blood pressure that were at least as strong as when
outcomes were measured post-menarche—likewise for the effect of later menarche on lower
odds of childhood obesity in the 2-sample MR setting—further indicating confounding of
puberty timing effects, likely by adiposity. Beyond reinforcing the need to adjust MR estimates
of puberty timing for a pre-pubertal measure of BMI, known overlap in genetic variants also
challenges the notion of puberty timing and adiposity being distinct phenomena.
Conceptual overlap certainly exists between pre-pubertal growth and pre-pubertal adiposity
(body size), with ‘age at puberty onset’ likely intended as a marker of the rate of pre-pubertal
growth. Overlap was also supported statistically by way of a high degree of heterogeneity in indi-
vidual puberty-variant effects on adult BMI in the 2-sample MR setting, suggesting that multiple
pathways of effect exist, although this heterogeneity appeared balanced. In MR terms, this could
therefore be a case of vertical rather than horizontal pleiotropy if genetic variants influence
puberty timing by first influencing pre-pubertal adiposity, which in turn brings puberty for-
ward. Primary effects of puberty-inducing variants could also operate via pathways unrelated to
pre-pubertal adiposity. Effects of puberty timing on later adiposity may therefore be genuine
but part of a wider chain of events in which pre-pubertal adiposity influences puberty timing,
which then further influences adiposity. Still, a literal and direct interpretation of age at puberty
onset within a confounding framework can serve as a means of interrogating these conceptual
overlaps and identifying a unifying root cause that can then be targeted for intervention.
Together with evidence of an effect of higher pre-pubertal BMI on earlier puberty onset, our
results support puberty timing as a marker, not a driver, of adiposity and cardiometabolic trait
levels, positioning childhood adiposity as a primary intervention target. Interventions are
important given results of a recent Danish study suggesting that moderately raised adiposity in
childhood (at age 7 y, before puberty) does not confer increased risk for type 2 diabetes in older
age if it does not persist into post-pubertal life stages [40]. Moderately raised adiposity during
puberty (age 13 y) conferred increased diabetes risk in older age whether it persisted or not, as
did very high childhood adiposity. Current MR results in ALSPAC support strong effects of
higher childhood adiposity on adulthood adiposity, indicating that exposure tends to persist.
Lifelong high exposure likely confers the greatest long-term diabetes risk [40].
Beyond blood pressure, generally weak evidence was found for causal associations of geneti-
cally instrumented later age at menarche among females with lipid- and glycaemic-related
traits derived from targeted metabolomics. Coefficients were practically null across VLDL,
IDL, LDL, HDL, and fatty acid traits, but slightly positive across glycolysis and amino acid
traits. All were accompanied by relatively weak levels of statistical significance, particularly
when considering a more stringent threshold corrected for multiple testing. Attenuations of
already weak associations after adjustment for pre-pubertal BMI were minimal, and changes
were instead often away from the null, likewise when adjusting for pre-pubertal values of spe-
cific trait outcomes. Association patterns across non-blood-pressure cardiometabolic traits
also differed when considering females and males combined, with coefficients generally being
positive across lipid-related and fatty acid traits and negative across amino acid traits; these
coefficients were largely uninfluenced by adjustment for pre-pubertal BMI. Despite larger
sample size, the reliability of the results in the sex-combined analyses is questionable given
markedly reduced instrument strength (the variance explained in exposure traits was
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approximately 11% among females versus approximately 2% among females and males com-
bined). Overall, the inconsistent association patterns across cardiometabolic traits are more
indicative of chance than robust causality.
Two-sample MR analyses were also conducted using publicly available GWAS data as a
means of external replication. Results supported effects of later age at puberty onset on lower-
ing adult BMI, and suggested associations with a range of adult cardiometabolic traits. Direc-
tions of effect were often opposite to those seen with 1-sample MR estimates however: negative
across lipid traits except HDL, and negative across fatty acids, amino acids, and inflammatory
glycoproteins. These patterns closely reflect what would be expected in response to lower adi-
posity [12] and likely indicate pleiotropy of puberty timing instruments with BMI. Two-sam-
ple models have the advantage of larger sample sizes and newly developed sensitivity methods
to account for directional pleiotropy, but only 1-sample models could account for adiposity
and cardiometabolic trait values as specifically measured before puberty onset. Results of one
recent MR study using UK Biobank data also support an effect of later puberty on lowering
adult BMI; this effect attenuated 2-fold when adjusting puberty-variant effects for their effect
on childhood BMI in the EGG consortium data using multivariate MR [39]. Genetic variants
used were based on an older GWAS and were fewer in number (122 versus up to 351 here),
and a P-value threshold for association with childhood BMI in EGG was relied upon for subse-
quent analyses; this is likely inadequate given strong residual associations of manually BMI-
pruned puberty GRSs with BMI [21]. Thus, it is likely that despite lower estimate precision in
our study due to smaller sample size, the attenuation patterns seen for adiposity in adjusted
1-sample MR models are most reflective of the influence of puberty timing itself.
Strengths and limitations
Key strengths of this study include its use of both prospective observational and genetically
informed analyses to address causality more comprehensively than previously possible. Repeat
data were used for BMI, objective fat mass, and over 200 detailed cardiometabolic traits mea-
sured before and after puberty onset, offering rare and extensive insight into temporality. Rep-
lications of 1-sample MR analyses were carried out using large-scale genetic data within a
2-sample MR setting on up to 322,154 adults. The strength of genetic instruments for puberty
timing was high among females in ALSPAC, explaining nearly 11% of exposure variance.
Limitations of this study include modest completion rates of puberty questionnaires in
ALSPAC (e.g., 58.4% among females), as is typical for sensitive topics; results here and else-
where are thus prone to selection bias. This proportion of responders is higher among those
with adiposity and cardiometabolic outcome data, at 83.2%, and comparisons suggested little
influence of selection on adiposity and cardiometabolic traits. Measurement error is likely
among those who did participate [41], especially among males [42] given the sporadic nature of
voice breaking. Estimates may therefore be less precise among males than among females. This
imprecision may have also made MR analyses of males prone to weak instrument bias, which
would bias association estimates towards the observational estimate in a 1-sample setting and
towards the null in a 2-sample setting. That evidence for association was generally weak in both
settings, as well as observationally, suggests that measurement imprecision is a core concern.
The non-blood-pressure cardiometabolic traits examined were heavily lipid-focused [30], and
relations of puberty timing with hormone-related traits such as insulin and insulin-like growth
factors were not examined. As noted, health behaviour covariates were not considered in obser-
vational analyses due to individual differences in exposure timing. Behaviours such as physical
activity are also subject to change over the course of puberty [43], and recorded levels in child-
hood may not represent levels in adolescence. The prevalence and duration of cigarette smoking
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and alcohol consumption are also expected to be low at puberty onset. In any case, MR analyses
negated the need for such covariates as risk alleles are expected to be distributed randomly [44].
Not all cardiometabolic traits were available for 2-sample MR analyses, but available traits cov-
ered most lipid subclass, fatty acid, amino acid, and inflammatory domains.
Participants not of a white-European ancestry were excluded to reduce confounding by
population stratification and because genetic variants for puberty timing were identified in
predominantly white-European samples. Future GWAS efforts could focus on other ethnic
ancestries to allow causal inference across diverse populations. The MR methods used assume
that modelled associations are linear. Some previous observational studies have suggested that
age at puberty onset may relate non-linearly to cardiometabolic and other diseases, with
increased risk apparently conferred by both early and late onset [45,46]. But the extent to
which these non-linear relations reflect genuine biology or confounding is unclear. Several
apparently non-linear associations, such as those observed between BMI and mortality [47]
and between alcohol consumption and cardiovascular disease [48], are not supported by
instrumental variable methods [49–52] and may therefore reflect confounding by subclinical
disease or social factors. Similar distortions of observed associations are possible with age at
puberty onset. Finally, despite extensive participant phenotyping, sample sizes for ALSPAC
analyses were modest. Substantial variance in age at menarche explained by its genetic instru-
ment afforded reasonable precision, however, and expectedly positive estimates of higher BMI
with higher SBP, DBP, and several other summary cardiometabolic traits at age 8 y and 18 y
provided further reassurance of adequate sample power.
Puberty spans several years for both sexes; the exposure of interest here was the age at
which it begins as this is what has been widely linked with health outcomes, cardiometabolic
and otherwise [46]. Data permitting, future studies among females could examine the full
duration of time between menarche and end of menopause to better capture lifetime exposure
to sex-hormone-related growth factors. Future work may also utilise observational and genetic
data on more objective and precise measures of puberty timing such as age at peak height
velocity [53]. Use of a 2-sample MR design allowed large sample sizes and for inferences to be
drawn from multiple cohorts. Relevant to this, however, is the issue of participant overlap
between exposure and outcome GWAS datasets, which may bias effect estimates towards the
confounding-prone observed association [54,55]. Potentially 25 of the 42 cohorts forming the
GWAS for age at menarche [21] were also part of the GWAS for BMI [28], while 3 of the age at
menarche cohorts may have also been part of the GWAS for metabolic traits [35]. A further 9
of the 114 cohorts for BMI may have also been part of the metabolic trait GWAS (this repre-
senting over half of the cohorts in the latter). Removing these participants from existing sum-
mary-level data is infeasible and would carry trade-offs including reduced power. This overlap
issue will become increasingly important with the growing scale of multi-cohort collaborations
and large-scale biobanks. Methodological advancements are needed to address this.
Conclusions
Results of this study suggest that age at puberty onset has only a small influence on adiposity
and cardiometabolic traits in adulthood because effects are largely confounded by pre-pubertal
adiposity. Strong evidence was also found for an effect of higher pre-pubertal adiposity on ear-
lier puberty onset, together pointing to childhood adiposity as a primary intervention target.
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(TIF)
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among females in ALSPAC, with adjustment for specific outcome trait values at age 8 y.
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(TIF)
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in ALSPAC, unadjusted (N = 2,054) and adjusted (N = 1,839) for measured BMI at age 8 y.
(TIF)
S14 Fig. Individual SNP effects of later age at menarche on fat mass index at age 18 y
among females in ALSPAC, unadjusted (N = 1,977) and adjusted (N = 1,780) for measured
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among females in ALSPAC, for comparisons with Fig 2.
(PDF)
S10 Table. Negative control 1-sample MR estimates of associations of age at menarche (per
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using a full GRS of 351 SNPs for age at menarche.
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